Introduction
Niemann-Pick disease type C (NPC) is a rare progressive neurodegenerative lysosomal disorder, which affects 1:100,000 live births 1, 2 . In addition to the central nervous system, the liver also plays a role in this disease, either presenting in infancy as cholestatic jaundice or if these patients survive as elevated levels of liver enzymes suggestive of chronic liver dysfunction 1 .
We recently discovered that the hepatic cytochrome P450 system is suppressed in the Npc1 null mouse model (Npc1 -/-), in the feline model of NPC disease and in three NPC human liver samples (post-mortem) 3 . In NPC, the efflux of unesterified cholesterol from late endosomes/lysosomes to the endoplasmic reticulum (ER) is inhibited, leading to a shift in the spectrum of bile acids synthesized 4, 5 , which suppresses gene expression of the P450 system 3 . Treatment of Npc1 -/-mice with ursodeoxycholic acid (UDCA; 3α, 7β-dihydroxy-5β-cholanic acid) rescued gene expression and P450 system enzyme activity 3 . In this study, we compared the effects of UDCA (soluble bile acid) and cholic acid (CA; hydrophobic bile acid) in the Npc1 -/-mouse and discovered hepatotoxic adverse effects on the liver in response to CA, but not to UDCA, suggesting UDCA is the bile acid of choice for clinical treatment of NPC patients.
Methods

Npc1 mouse model Npc1 mutant (BALB/cNctr-Npc1m1N/J, Npc1
-/-) and control (Npc1 +/+ ) were generated from heterozygote breeding. Genotyping was performed as described 6 and mixed sex groups analysed. All mice were maintained under a standard 12h light/12h dark cycle with water and food available ad libitum. All procedures were performed according to the Animals (Scientific Procedures) Act 1986 under a project license (PPL No. 30/2923) from the UK Home Office. Care was taken to minimise suffering through euthanizing the animals once liver enlargement was unambiguously detected by visual inspection (i.e. 3 weeks after initiation of treatment).
Bile acid supplementation
Npc1
-/-and Npc1 +/+ mice (n = 9-17 per group) were fed either normal chow (RM1 maintenance diet; SDS, London, UK) or normal chow supplemented with UDCA (0.5%, w/w, Sigma-Aldrich) or CA (0.5%, w/w, Sigma-Aldrich) mixed with powdered diet. Treatment started at weaning (3 weeks of age) and mice were sacrificed at 6 weeks of age by intraperitoneal injection with an overdose of phenobarbital.
Histology
Animals were euthanized at 6 weeks of age and were trans-cardiac perfused with 4% paraformaldehyde (PFA); samples of liver were fixed in 4% PFA, dehydrated and processed to wax using standard procedures. The wax blocks were cut at 4-μm-thick sections, mounted on SuperFrost Plus slides (Thermo Scientific, Waltham, MA, USA) and subjected to hematoxylin and eosin (H&E) staining by standard methods. Images were taken on a Nikon eclipse E200 microscope with a Leica digital camera system. Figure 1D ) showed the typical vacuolated appearance of the liver characteristic of Npc1 -/-mice relative to wild type mice. UDCA treatment had no impact on the histopathology of wild type and Npc1 -/-mice, whereas CA treatment led to hepatocyte enlargement and a foamy appearance indicative of lipid accumulation that often displaced the nucleus to the pole of the cell.
Statistical analysis
Discussion
NPC disease cells display a complex cellular pathophysiology, including impaired movement of LDL-derived cholesterol from late endosomes/lysosomes to the ER 8 and the generation of nonenzymatically generated oxysterols 9 . As a consequence, the bile acid profile is altered in NPC disease 4, 5 , and this change in bile acid composition leads to a secondary suppression of the P450 gene family, as they are bile acid regulated 3 . The expression of the P450 system genes could be rescued in Npc1 -/-mice by administering the bile acid UDCA, leading to clinical benefit 3 . In another study, UDCA was trialed in four clinical NPC cases and liver function improved in patients with elevated liver enzymes at baseline 10 .
In this study, we investigated whether CA, another bile acid used in routine clinical practice for bile acid disorders 11 would also be beneficial. Therefore, we treated Npc1 -/-mice with UDCA or CA to investigate this further. However, three weeks into the treatment the CA mice presented with gross abdominal distension so they were culled to determine the basis for this adverse finding. It was clear on gross necropsy that the livers were significantly enlarged in CA treated wild type and Npc1 -/-mice, and when we adjusted for body weight it was apparent that the liver enlargement was greater in the Npc1 -/-mice relative to Npc1
. Looking at the adjusted liver weight with the body weight, CA treated wild type mice had increased liver volume of 165.5% when compared with untreated wild type, whereas the Npc1 -/-mice showed 179.1% increase in liver volume when compared with the untreated Npc1 -/-mice.
Histopathology revealed lipid laden distended hepatocytes in the CA treated Npc1 -/-mice. These data suggest CA is more hepatotoxic in mice than UDCA, consistent with the differential chemical properties of these two bile acids. The NPC1 protein, deficient in most cases of NPC disease, is a conserved member of a protein family, the RND permeases 12 . In bacterial systems they serve to efflux multiple classes of substrates across the periplasmic space, allowing bacteria to thrive in hostile environments 13 . CA's hydrophobic chemistry suggest it may be a potential substrate for NPC1 13 , so it may itself be stored in the late endocytic system in NPC1 deficient cells and adversely affect the acidic compartment of the cell leading to further lipid storage. This hypothesis merits further investigation.
When four NPC1 patients were treated with UDCA, benefit was observed based on improved liver function 10 . Very interestingly, one patient was switched from UDCA to CA and their clinical status declined but was recovered on switching back to UDCA, and this has striking parallels with this study in mice. Taken together, these data strongly support the use of UDCA as an adjunctive therapy to treat residual liver disease in NPC patients, but CA is contraindicated due to acute hepatotoxicity that is most pronounced in an NPC1 deficient background.
Data availability
Raw data have been uploaded to the online data repository OSF: http://dx.doi.org/10.17605/OSF.IO/5A2F9
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Although the dietary level of BA supplementation employed is in line with what is often used in animal models, the changes in bile acid pool and composition that ensue when the amount of dietary BA is set at 0.5% w/w are beyond extreme and result in shifts in cholesterol metabolism at multiple levels that would never occur in humans taking approved doses of any specific BA. At a dietary level of 0.5%, the dose used in these studies was the equivalent of around 800 mg/day /kg bw which far exceeds what most human subjects taking oral BAs consume during a 24 hour period. When BA pool size and composition change in extreme ways there are invariably marked shifts in intestinal cholesterol absorption and this in turn has a major impact on the amount of chylomicron cholesterol reaching the liver from the small intestine (and therefore in the amounts of unesterified chol -UC-becoming subsequently trapped in the late /E/L compartment when NPC1 or NPC2 are mutated). There is an excellent study by Wang (2003) showing how a range of et al. BAs including UDCA and CA (added to the diet at a level of 0.5%) affect intestinal cholesterol absorption in a normal mouse model (see Fig 3 in particular) . While a BA pool enriched with UDCA drives down intestinal cholesterol absorption, the opposite effect occurs with CA. Another example illustrating how BA pool size and composition are major determinants of cholesterol absorption is seen in a study by Schwarz (1998) -see solid histograms for WT mice given hyodeoxycholic et al. acid vs cholic acid in Fig 5. Anyone who knows about the properties of CA and who also understands the biochemical consequences of NPC1 deficiency would view the effects of CA described in the current report as "totally predictable" especially given the massive dose that was fed to the mice. It would have been better to use two different doses of UDCA.
The bottom line in all this is that the differing impacts on liver "health" of UDCA vs CA supplementation in NPC1 mice shown here are likely fully explainable on the basis of major differences in the amount of intestinally derived cholesterol trapped in the livers of the KOs given these two particular BAs. Although no data are presented for hepatic total chol concs (mg/g), one might predict from other studies in the NPC1 mouse model that a several fold greater level of unesterified chol (UC) would be seen in the livers of the CA supplemented mice vs those given UDCA. There is no question that it is the cytotoxic effects of the entrapped UC in all organs, especially the liver, that has the most damaging impact in NPC1 (or NPC2) dysfunction.
While it is recognized that this is a preliminary report, it is essential that more informed conclusions be reached about what UDCA supplementation might conceivably be doing in the human NPC1-deficient liver. To achieve this, definitely the liver UC and EC concentrations in these mice, along with their plasma/serum ALT and AST levels should be measured. Such measurements are needed if these mouse model experiments are to provide any credible guide as to how UDCA supplementation in human NPC1 patients might be acting. The benefit most likely has nothing to supplementation in human NPC1 patients might be acting. The benefit most likely has nothing to do with putative improvement in functionality of the P450 detoxification system.
As it is currently written, this report will likely attract criticism because of its lack of acknowledgement of significant published work documenting the beneficial impact of other types of treatment modalities for improving liver function in NPC1 deficiency, mostly based on in vivo experiments using primarily the NPC1 mouse model. In 2007 Beltroy showed that the et al. cholesterol absorption inhibitor, ezetimibe, given in the diet from the time of weaning, at doses far below those of other treatments (ie 20 or less mg /day/kg bw), reduced hepatomegaly and lowered liver cholesterol content (nearly all UC) by almost 50% (Fig 4) . The benefit of ezetimibe in this disease is largely in the liver. After that, a series of definitive publications from a number of labs attesting the potency of subcutaneously administered 2HPBCD in diminishing hepatic UC content and markedly improving liver function tests (and increasing lifespan) in NPC1 mouse models helped establish this agent as one of great potential for managing multisystem disease in NPC1 deficiency .
Although this preliminary report will be of interest to many working in the field of NPCD management, it should not generate the impression that UDCA has a clear potential to become a treatment modality for liver disease in NPCD patients. Citation of the earlier papers noted above documenting the decisive benefits of ezetimibe and 2HPBCD in NPC1 mice will allow readers to gain a better perspective of what these initial data in the UDCA treated NPC1 mouse model are telling us. "Differential response of the liver to bile acid treatment in a mouse reports the effect of bile acid treatment on the liver pathology model of Niemann-Pick disease type C" in a mouse model of NPC disease. Although, NPC is primarily considered a neurodegenerative disease, defects in systemic organs including liver have been seen in many patients. The authors previously reported suppression of cytochrome P450 detoxification system in the liver of NPC mice and limited set of human samples. Cytochrome P450 enzymes are also involved in the synthesis of bile acids from cholesterol. The authors hypothesize that exogenously supplied bile acid could potentially alleviate liver disease in NPC. In the study, they used a mouse model to test the hypothesis. The study comes from a lab that holds expertise in NPC and actively advancing the NPC research since last many years. The study was elegantly designed, results are clearly presented and the manuscript is well written and discussed. The conclusions drawn are based on the results reported. The manuscript is suitable to be published in the current form, however if the authors addressed the following comments, it would further enhance the quality of this publication.
In NPC, many systemic organs including liver show elevated inflammation. One would expect decreased cholesterol burden after UDCA treatment would reduce infiltration of inflammatory cells such as macrophages and neutrophils. It would be nice to have results of a couple of inflammatory marker analysis included in the liver of UDCA treated mice. In addition, it would also be interesting to see how liver enzymes (such as ALT & AST) in mice respond to UDCA treatment.
In a separate manuscript (submitted for peer review, ref #10), the authors report the clinical data of four NPC patients treated with bile acid. The results presented in ref#10 show significant improvement in the liver function in UDCA-treated patients. The submission is a useful extension of this study and shows how findings in an animal model translate to clinics. I would have preferred if both manuscripts were combined. This would allow readers to have a better understanding of the effect of bile acid treatment in NPC in the mouse model as well as in clinics without going through 2. both manuscripts were combined. This would allow readers to have a better understanding of the effect of bile acid treatment in NPC in the mouse model as well as in clinics without going through two separate publications. Nevertheless, this manuscript on its own reports interesting findings. 
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